Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430767 · ClinicalTrials.gov registry record
Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
A clinical trial of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 33
- Enrollment target
- 1
- Study location
NCT01430767: Completed study of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Wake Forest University Health Sciences.
NCT01430767 is a study of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder (ADHD) that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 33 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430767, a study of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder (ADHD), has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Poor adherence is a common reason for treatment failure in many fields of medicine, and likely affects common psychiatric treatments as well. Members of the present study team have used Medication Event Monitoring System (MEMS®) caps effectively to objectively monitor adherence in skin disease, and have shown that they provide a much more accurate measure of adherence behavior than self-reports, pill counts, or serum drug concentrations. The present study will use MEMS® caps to measure adherence in 10 patients with depression and 10 patients with attention-deficit hyperactivity disorder (ADHD) from a student clinic population. The aims will be to show the usefulness of MEMS® caps in measuring adherence to psychiatric treatment, and gather data on typical adherence rates for depression and ADHD patients on typical treatment regimens. The data obtained will be used to inform future studies that use an intervention to improve adherence behavior and ultimately disease outcomes.
Primary Outcome
Adherence to standard-of-care medication for depression or ADHD will be objectively measured using a bottle fitted with a Medication Event Monitoring System (MEMS®) cap and the percentage of prescribed doses taken will be reported as the outcome.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-12 |
What the finished NCT01430767 record still lists
NCT01430767 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT01430767 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01430767 about?
NCT01430767 is a clinical study titled "Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder". Poor adherence is a common reason for treatment failure in many fields of medicine, and likely affects common psychiatric treatments as well. Members of the present study team have used Medication Event Monitoring System (MEMS®) caps effectively to objectively monitor adherence in skin disease, and ...
What is the current status of trial NCT01430767?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2011-09. Estimated completion is 2014-12.
What conditions does trial NCT01430767 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Attention Deficit Hyperactivity Disorder (ADHD).
Who is sponsoring clinical trial NCT01430767?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430767 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01430767's enrollment target sits among peer trials
33 217th of 282 higher than 66 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia